Goldman Sachs significantly raises price target for Novo Nordisk – Wegovy pill comes into focus

Goldman Sachs provides fresh buying arguments for Novo Nordisk. The US investment bank has significantly raised the price target for the Danish pharmaceutical company from 352 to 436 Danish Kroner (DKK) and confirmed the rating of "Buy" . Analyst James Quigley sees the new Wegovy pill as a massive short-term catalyst for sentiment and results. The main driver: "Oral Wegovy" as a catalyst for 2026 At the center of the optimistic assessment is the expectation that a two-stage news and demand catalyst will build around the pill in 2026. This follows...